Please assess the completion status of the following clinical trial:

Trial Title: Mirabegron and Urinary Urgency Incontinence

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Bothersome idiopathic (non-neurologic) urgency urinary incontinence (UUI) who recall ≥ 5 urgency predominant urinary incontinence episodes in the prior week (urgency urinary incontinence or mixed urinary incontinence-urgency predominant)~* No contraindications to taking mirabegron~* Patients on current OAB therapy will undergo a two-week drug washout period prior to baseline assessment~Exclusion Criteria:~* Neurologic disease known to affect the lower urinary tract~* Systemic immunologic deficiency~* Current urinary tract infection (UTI) (based on dipstick assessment) or recurrent culture-proven UTIs~* History or current pelvic malignancy or radiation~* Untreated symptomatic pelvic organ prolapse (POP) \> POP-Q Stage II~* A contraindication to receiving mirabegron~* Women of childbearing potential who are pregnant or nursing or intend to become pregnant during the study, or who are not practicing a reliable method of contraception~* Must not have taken any antibiotics in the 4 weeks prior to enrollment

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Mirabegron (Type: EXPERIMENTAL): Participants received mirabegron (Myrbetriq) daily for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).